Ogalon joins hands with JD Health to explore innovative practices in blood lipid health management

On November 6, at the 9th China International Import Expo, Ogalon, the world's leading medical and health company, and JD Health jointly launched a blood lipid health management innovation project. The two parties will combine Ogallon's professional accumulation in the field of cardiovascular health and JD Health's digital platform advantages to explore the integration of more blood lipid health management-related services into patients' drug purchase scenarios to help the public improve their awareness of blood lipid health and active management awareness.

Zafer Unluer, President of Algalon China, Lin Yuwei, Vice President and Head of Marketing of Algalon China, Cao Dong, SEC member of JD Group and CEO of JD Health, Song Zhirui, Vice President of JD Group and General Manager of JD Health’s pharmaceutical business, attended the “Algalon x JD Health Blood Lipid Health Management Innovation Project” event

Cardiovascular disease has become one of the important diseases affecting the health of Chinese residents, and dyslipidemia is an important risk factor. For many patients, standardizing medication is only the first step in health management. How to continue to pay attention to one's own health status, maintain long-term management awareness, and obtain convenient management support are still important issues facing out-of-hospital health management.

As the leading online medical and health platform in China, JD Health relies on its pharmaceutical supply chain, medical services and health management capabilities to build a service scenario inside and outside the hospital covering "medicine - diagnosis - medicine - health management", with more than 200 million annual active users. Relying on its high-frequency drug purchase scenarios and digital touch points, the two parties will explore the innovative implementation of health science popularization, patient education and blood lipid management services around the cardiovascular brand Ezetimibe® (Ezetimibe Tablets), a brand owned by Alcalon, to help more people increase their attention and awareness of blood lipid health and understand the importance of standardized management.

With the help of the open platform of the CIIE, the cooperation between Ogalon and JD Health continues to deepen. Since the first collaboration at the fifth CIIE in 2022, the two parties have continued to expand the boundaries of cooperation around patient needs, from the construction of online flagship stores, the introduction of innovative products, to the exploration of health service models, and continue to promote high-quality medical and health resources to reach more patients. The launch of the blood lipid health management innovation project also marks the further extension of the cooperation between the two parties from drug access to the exploration of blood lipid health management services, and promotes the expansion of out-of-hospital blood lipid health management from drug supply to comprehensive health services.

Song Zhirui, vice president of JD Group and general manager of JD Health's pharmaceutical business, said: "As public health awareness continues to increase, more and more users want to obtain more health service support in addition to purchasing medicines. Relying on digital platform capabilities, AI technology, and online and offline integrated service scenarios, JD Health and Ogalon jointly launched the blood lipid health management innovation project, hoping to use the high-frequency touch point of drug purchase to bring blood lipid health-related services closer to users and help more people implement health management into their daily actions."

Lin Yuwei, vice president and head of marketing department of Algalon China, said: "Ogalon always adheres to patient needs as the center. We not only focus on the accessibility of innovative drugs and high-quality treatment options, but also continue to explore how to support patients' long-term blood lipid health management through richer service scenarios. This time we join hands with JD Health, hoping to leverage the advantages of both parties, further integrate professional disease management support into the health management scenario, help more people pay attention to blood lipid health, and promote the extension of health management from one-time drug purchases to continuous health concerns."

In the future, Ogallon and JD Health will continue to deepen their cooperation around patient needs, explore innovative applications of digital services in the field of blood lipid management, and provide the public with more convenient and continuous management support.